Two Cases of Porokeratosis with MVD Mutations, in Association with Bullous Pemphigoid

Authors

  • Yuki Arisawa
  • Yasutoshi Ito
  • Kana Tanahashi
  • Yoshinao Muro
  • Tomoo Ogi
  • Takuya Takeichi Department of Dermatology, Nagoya University Graduate School of Medicine, 466-8560 Nagoya, Japan
  • Masashi Akiyama

DOI:

https://doi.org/10.2340/00015555-3764

Keywords:

autoinflammation, mevalonate pathway, mutation

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Leng Y, Yan L, Feng H, Chen C, Wang S, Luo Y, et al. Mutations in mevalonate pathway genes in patients with familial or sporadic porokeratosis. J Dermatol 2018; 45: 862-866.

DOI: https://doi.org/10.1111/1346-8138.14343

Takeichi T, Akiyama M. Familial or sporadic porokeratosis as an autoinflammatory keratinization disease. J Dermatol 2019; 46: e125-e126.

DOI: https://doi.org/10.1111/1346-8138.14666

Taki T, Takeichi T, Kono M, Sugiura K, Sugimura Y, Ishii N, et al. A patient with bullous pemphigoid with mucosal involvement serologically positive for anti-BP230 autoantibodies only. Br J Dermatol 2020; 182: 221-223.

DOI: https://doi.org/10.1111/bjd.18343

Zhang Z, Li C, Wu F, Ma R, Luan J, Yang F, et al. Correction: genomic variations of the mevalonate pathway in porokeratosis. Elife 2016; 5: e14383.

DOI: https://doi.org/10.7554/eLife.14383

Atzmony L, Khan HM, Lim YH, Paller AS, Levinsohn JL, Holland KE, et al. Second-hit, postzygotic PMVK and MVD mutations in linear porokeratosis. JAMA Dermatol 2019; 155: 548-555.

DOI: https://doi.org/10.1001/jamadermatol.2019.0016

Atzmony L, Lim YH, Hamilton C, Leventhal JS, Wagner A, Paller AS, et al. Topical cholesterol/lovastatin for the treatment of porokeratosis: a pathogenesis-directed therapy. J Am Acad Dermatol 2020; 82: 123-131.

DOI: https://doi.org/10.1016/j.jaad.2019.08.043

Kubo A, Sasaki T, Suzuki H, Shiohama A, Aoki S, Sato S, et al. Clonal expansion of second-hit cells with somatic recombinations or C>T transitions form porokeratosis in MVD or MVK mutant heterozygotes. J Invest Dermatol 2019; 139: 2458-2466.e9.

DOI: https://doi.org/10.1016/j.jid.2019.05.020

den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat 2016; 37: 564-569.

DOI: https://doi.org/10.1002/humu.22981

Schamroth JM, Zlotogorski A, Gilead L. Porokeratosis of Mibelli. Overview and review of the literature. Acta Derm Venereol 1997; 77: 207-213.

Buhl T, Wienrich BG, Sieblist C, Schon MP, Seitz CS. Development of segmental superficial actinic porokeratosis during immunosuppressive therapy for pemphigus vulgaris. Acta Derm Venereol 2010; 90: 212-213.

DOI: https://doi.org/10.2340/00015555-0800

Published

2021-03-31

How to Cite

Arisawa, Y., Ito, Y., Tanahashi, K., Muro, Y., Ogi, T., Takeichi, T., & Akiyama, M. (2021). Two Cases of Porokeratosis with MVD Mutations, in Association with Bullous Pemphigoid. Acta Dermato-Venereologica, 101(3), adv00423. https://doi.org/10.2340/00015555-3764

Issue

Section

Short Communication

Categories